xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06034834</url>
    </required_header>
    <id_info>
      <org_study_id>NL84014.058.23</org_study_id>
      <nct_id>NCT06034834</nct_id>
    </id_info>
    <brief_title>Near-Infrared Imaging for Perfusion Assessment of Traumatic Soft Tissue and Skeletal Injuries</brief_title>
    <acronym>IMPACT</acronym>
    <official_title>Near-Infrared Imaging for Perfusion Assessment of Traumatic Soft Tissue and Skeletal Injuries</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Leiden University Medical Center</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Erasmus Medical Center</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Leiden University Medical Center</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        To date, intraoperative assessment of tissue and bone viability is predominantly subjective,&#xD;
        depending on the clinical view of the surgeon, resulting in a variation in the thoroughness&#xD;
        of debridement. Inadequate initial resection leads to multiple debridement interventions,&#xD;
        leading to prolonged hospitalization or readmission with consequently high direct medical&#xD;
        costs.&#xD;
  &#xD;
        Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) could potentially be a&#xD;
        relevant contribution to adequately treating soft tissue and skeletal injuries by creating an&#xD;
        improved distinction between viable and non-viable tissue, based on perfusion indices.&#xD;
  &#xD;
        This study evaluates whether intraoperative perfusion assessment with ICG fluorescence&#xD;
        imaging is a feasible and quantifiable technique for treating traumatic injuries.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Rationale: In 2020 71.623 Dutch patients were acutely admitted to hospitals due to sustained&#xD;
        traumatic injuries. 7% of the injuries related to open wounds and 44% to fractures. The&#xD;
        majority of traumatic musculoskeletal injuries needs to be diagnosed and treated as soon as&#xD;
        possible to lower the risk of infections and to minimize adverse outcome, such as necrosis&#xD;
        and/or osteomyelitis. To date, intraoperative assessment of tissue and bone viability is&#xD;
        predominantly subjective, resulting in a variation in thoroughness of debridement. If not all&#xD;
        necrotic tissue is removed, suboptimal healing occurs, which serves as a potential food&#xD;
        source for bacteria. In addition, inadequate initial resection leads to multiple debridement&#xD;
        interventions, leading to prolonged hospitalization or readmission with consequently high&#xD;
        direct medical costs. Since tissue necrosis is an ongoing process, radical resection of&#xD;
        avital tissue during the initial procedure is not always possible. The surgeon's visual&#xD;
        estimation is not optimal to predict the final amount of debridement. After maximal&#xD;
        debridement, antibiotic treatment and coverage of open wounds, the incidence of infection can&#xD;
        rise to 27%. Compromised perfusion is at the centre of this problem. An adequate blood supply&#xD;
        is crucial for tissue viability and infection clearance.&#xD;
  &#xD;
        Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) has already shown its&#xD;
        potential in effective real-time assessment of intra-operative tissue perfusion and the early&#xD;
        prediction of future necrosis in multiple studies. This technique could potentially be a&#xD;
        relevant contribution in adequately treating soft tissue and skeletal injuries by creating an&#xD;
        improved distinction between viable and non-viable tissue, based on perfusion indices.&#xD;
        However to date, the feasibility to quantify this technique in posttraumatic tissue has not&#xD;
        been successfully evaluated.&#xD;
  &#xD;
        Objective: The primary objective of this study is to evaluate the feasibility of&#xD;
        Near-infrared Fluorescence (NIRF) imaging with Indocyanine green (ICG) to assess and quantify&#xD;
        tissue perfusion in post-traumatic soft tissue and/or skeletal injury.&#xD;
  &#xD;
        Study design: The study is a prospective observational multicentre pilot study. All included&#xD;
        patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion&#xD;
        assessment will not affect treatment of patients.&#xD;
  &#xD;
        Study population: Patients aged 18 years or older with traumatic soft tissue and/or skeletal&#xD;
        injury. Injuries included in the study are: open deglovement; crush injuries of extremities;&#xD;
        open fractures, non-unions of clavicula, tibia, humerus, rib and/or ulna fractures and&#xD;
        fracture related infections.&#xD;
  &#xD;
        Intervention: Patients will undergo an intra-operative perfusion assessment using ICG NIR&#xD;
        fluorescence imaging. For patients undergoing additional debridement procedures, perfusion&#xD;
        assessment with ICG will be repeated during every procedure.&#xD;
  &#xD;
        Main study parameters/endpoints: The primary outcome of this study is a time-intensity curve&#xD;
        with quantified perfusion parameters in traumatic soft tissue and/or skeletal injuries.&#xD;
        Perfusion parameters included in the analyses are time till maximum intensity (Tmax), maximum&#xD;
        intensity (Imax) the ingress rate, the normalized slope, the absolute slope and the area&#xD;
        under the curve at 30, 60 and 120 seconds.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 10, 2023</start_date>
    <completion_date type="Anticipated">November 10, 2025</completion_date>
    <primary_completion_date type="Anticipated">September 10, 2025</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <intervention_model_description>The study is a prospective observational multicentre pilot study. All included patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion assessment will not affect the treatment of patients.</intervention_model_description>
      <primary_purpose>Diagnostic</primary_purpose>
      <masking>None (Open Label)</masking>
      <masking_description>The surgeons will be blinded as to the results of the intraoperative perfusion assessment in order to prevent bias.</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Time-intensity curves</measure>
      <time_frame>1 day</time_frame>
      <description>The main endpoint of this study is an adequate time-intensity curve extracted from selected regions of interest. Adequate curves are defined as reproducible curves with accurate representation of the perfusion status. An adequate curve is characterized by a recognisable in- and outflow pattern representing the bloodflow in the tissue. Distinguishing between adequate, questionable and inadequate perfusion can only be done after comparing the measurement results.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Maximum intensity (Imax)</measure>
      <time_frame>1 day</time_frame>
      <description>As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:&#xD;
  • Maximum intensity (Imax) in arbitrary units (a.u.)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time till maximum intensity (Tmax)</measure>
      <time_frame>1 day</time_frame>
      <description>As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:&#xD;
  • Time till maximum intensity (Tmax), in seconds.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The ingress rate and absolute slope</measure>
      <time_frame>1 day</time_frame>
      <description>As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:&#xD;
  The ingress rate&#xD;
  The absolute slope Both in arbitrary units per second (a.u./s)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The normalized slope</measure>
      <time_frame>1 day</time_frame>
      <description>As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:&#xD;
  • The normalized slope in percentages per second (%/s)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The area's under the curve at 30, 60 and 120 seconds</measure>
      <time_frame>1 day</time_frame>
      <description>As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:&#xD;
  • Area under the curve at 30, 60 and 120 seconds in percentages (%)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Incidence of necrotic tissue</measure>
      <time_frame>90 days of necrotic</time_frame>
      <description>Perfusion parameters will be evaluated for their correlation with the occurrence of necrotic tissue after initial debridement.&#xD;
  This will be calculated as the percentage of people with inadequate perfusion parameters that develop necrotic tissue compared to people with adequate perfused tissue.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The amount of additional debridement procedures</measure>
      <time_frame>90 days</time_frame>
      <description>The number of additional debridement procedures when comparing the group with inadequate perfused tissue to the group with adequate perfused tissue.&#xD;
  In numbers and percentages.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The infection incidence</measure>
      <time_frame>90 days</time_frame>
      <description>Perfusion parameters will be evaluated for their correlation with the occurrence of wound infection within 90 days after procedure. Infection defined as a red, swollen and painful area that is warm and tender to touch, possibly in combination with fever/chills, purulent effusion, positive cultures or increased infection parameters. The group with adequate perfused tissue will be compared to the group with inadequate perfusion.&#xD;
  This will be in numbers and percentages.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The incidence of a fracture related infection</measure>
      <time_frame>90 days</time_frame>
      <description>Incidence of a fracture related infection will be compared between the groups with adequate and inadequate perfusion in numbers and percentages.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Lentgh of hospital stay</measure>
      <time_frame>90 days</time_frame>
      <description>The length of hospital stay will be measured in days and compared between groups with adequate and inadequate perfusion.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Amount of readmission</measure>
      <time_frame>90 days</time_frame>
      <description>The number of readmissions within 90 days associated with complications of primary problem (infection, necrosis, death) will be compared between the groups with inadequate and adequate tissue perfusion in numbers and percentages.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">120</enrollment>
    <condition>Perfusion</condition>
    <condition>Traumatic Injury</condition>
    <condition>Fluorescence Imaging</condition>
    <arm_group>
      <arm_group_label>Traumatic injuries</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Acute patients treated surgically for:&#xD;
  Open deglovement (n=20)&#xD;
  Crush injury (n=20)&#xD;
  Open fractures (n=20)&#xD;
  The setting is defined acute when there is less than 24 hours between sustaining the injury and surgery.&#xD;
  Elective patients treated surgically for:&#xD;
  Fracture related infection (FRI) (n=10)&#xD;
  Non-union of fractures (n=50) Subdivided into 5 groups of 10.&#xD;
  Elective osteosynthesis of non-union clavicula fracture N=10&#xD;
  Primarily operated on N=5&#xD;
  Primarily treated conservatively N=5&#xD;
  Elective osteosynthesis of non-union tibia. N=10&#xD;
  Elective osteosynthesis of non-union ulna. N=10&#xD;
  Primarily operated on N=5&#xD;
  Primarily treated conservatively N=5&#xD;
  Elective osteosynthesis of non-union humerus. N=10&#xD;
  Elective osteosynthesis of non-union of the rib. N=10</description>
    </arm_group>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>Near-infrared fluorescence imaging of perfusion</intervention_name>
      <description>Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.</description>
      <arm_group_label>Traumatic injuries</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          In order to be eligible to participate in this study, a subject must meet all the following&#xD;
          criteria:&#xD;
  &#xD;
            -  Age ≥ 18 years&#xD;
  &#xD;
            -  Diagnosed with one or more of the following injuries:&#xD;
  &#xD;
                 -  Crush injury&#xD;
  &#xD;
                 -  Open deglovement&#xD;
  &#xD;
                 -  Open fracture(s) (Gustilo 3, -A, -B &amp; -C)&#xD;
  &#xD;
                 -  Non-union tibia/clavicula/ulna/humerus/rib&#xD;
  &#xD;
                 -  Fracture related infection&#xD;
  &#xD;
            -  Indication for surgical intervention&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          A potential subject who meets any of the following criteria will be excluded from&#xD;
          participation in this study:&#xD;
  &#xD;
            -  Hemodynamically unstable due to severe blood loss&#xD;
  &#xD;
            -  Allergic or hypersensitive to iodine/crustaceans/shellfish&#xD;
  &#xD;
            -  Diagnosed with endocrine thyroid disorders (hyperthyroidism)&#xD;
  &#xD;
            -  Pregnancy&#xD;
  &#xD;
            -  Diagnosed with impaired renal function eGFR &lt;30 L/min/1.73m2&#xD;
  &#xD;
            -  Diagnosed with severely disturbed hepatic enzymes/liver failure&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Stefan Koning, MD</last_name>
      <role>Study Director</role>
      <affiliation>Leiden University Medical Center</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Joost R van der Vorst, MD, PhD</last_name>
      <phone>+31715298528</phone>
      <email>j.r.van_der_vorst@lumc.nl</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Inger B Schipper, Prof. MD, Phd</last_name>
      <phone>+31715265025</phone>
      <email>i.b.schipper@lumc.nl</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Leiden University Medical Center</name>
        <address>
          <city>Leiden</city>
          <state>Zuid-Holland</state>
          <zip>2333ZA</zip>
          <country>Netherlands</country>
        </address>
      </facility>
      <contact>
        <last_name>Joost R van der Vorst, MD, PhD</last_name>
        <phone>+3175298528</phone>
        <email>j.r.van_der_vorst@lumc.nl</email>
      </contact>
      <contact_backup>
        <last_name>Inger B Schipper, Prof. MD, PhD</last_name>
        <phone>+31715265025</phone>
        <email>i.b.schipper@lumc.nl</email>
      </contact_backup>
      <investigator>
        <last_name>Stefan Koning, MD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Erasmus University Medical Center</name>
        <address>
          <city>Rotterdam</city>
          <state>Zuid-Holland</state>
          <zip>3000 CA</zip>
          <country>Netherlands</country>
        </address>
      </facility>
      <contact>
        <last_name>Mathieu M.E. Wijffels, MD, PhD</last_name>
        <phone>+3107032395</phone>
        <email>m.wijffels@erasmusmc.nl</email>
      </contact>
    </location>
    <location_countries>
      <country>Netherlands</country>
    </location_countries>
    <verification_date>September 2023</verification_date>
    <study_first_submitted>August 29, 2023</study_first_submitted>
    <study_first_submitted_qc>September 5, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">September 13, 2023</study_first_posted>
    <last_update_submitted>September 5, 2023</last_update_submitted>
    <last_update_submitted_qc>September 5, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">September 13, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
      <investigator_full_name>jrvandervorst</investigator_full_name>
      <investigator_title>Dr. Joost van der vorst, Vascular Surgeon</investigator_title>
    </responsible_party>
    <keyword>Indocyanine Green</keyword>
    <keyword>Near-infrared fluorescence imaging</keyword>
    <keyword>Traumatic injuries</keyword>
    <keyword>Perfusion</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Wounds and Injuries</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06034834
  org study id: NL84014.058.23
  nct id: NCT06034834
  lead sponsor: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  To date, intraoperative assessment of tissue and bone viability is predominantly subjective,
        depending on the clinical view of the surgeon, resulting in a variation in the thoroughness
        of debridement. Inadequate initial resection leads to multiple debridement interventions,
        leading to prolonged hospitalization or readmission with consequently high direct medical
        costs.
  
        Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) could potentially be a
        relevant contribution to adequately treating soft tissue and skeletal injuries by creating an
        improved distinction between viable and non-viable tissue, based on perfusion indices.
  
        This study evaluates whether intraoperative perfusion assessment with ICG fluorescence
        imaging is a feasible and quantifiable technique for treating traumatic injuries.
  Rationale: In 2020 71.623 Dutch patients were acutely admitted to hospitals due to sustained
        traumatic injuries. 7% of the injuries related to open wounds and 44% to fractures. The
        majority of traumatic musculoskeletal injuries needs to be diagnosed and treated as soon as
        possible to lower the risk of infections and to minimize adverse outcome, such as necrosis
        and/or osteomyelitis. To date, intraoperative assessment of tissue and bone viability is
        predominantly subjective, resulting in a variation in thoroughness of debridement. If not all
        necrotic tissue is removed, suboptimal healing occurs, which serves as a potential food
        source for bacteria. In addition, inadequate initial resection leads to multiple debridement
        interventions, leading to prolonged hospitalization or readmission with consequently high
        direct medical costs. Since tissue necrosis is an ongoing process, radical resection of
        avital tissue during the initial procedure is not always possible. The surgeon's visual
        estimation is not optimal to predict the final amount of debridement. After maximal
        debridement, antibiotic treatment and coverage of open wounds, the incidence of infection can
        rise to 27%. Compromised perfusion is at the centre of this problem. An adequate blood supply
        is crucial for tissue viability and infection clearance.
  
        Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) has already shown its
        potential in effective real-time assessment of intra-operative tissue perfusion and the early
        prediction of future necrosis in multiple studies. This technique could potentially be a
        relevant contribution in adequately treating soft tissue and skeletal injuries by creating an
        improved distinction between viable and non-viable tissue, based on perfusion indices.
        However to date, the feasibility to quantify this technique in posttraumatic tissue has not
        been successfully evaluated.
  
        Objective: The primary objective of this study is to evaluate the feasibility of
        Near-infrared Fluorescence (NIRF) imaging with Indocyanine green (ICG) to assess and quantify
        tissue perfusion in post-traumatic soft tissue and/or skeletal injury.
  
        Study design: The study is a prospective observational multicentre pilot study. All included
        patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion
        assessment will not affect treatment of patients.
  
        Study population: Patients aged 18 years or older with traumatic soft tissue and/or skeletal
        injury. Injuries included in the study are: open deglovement; crush injuries of extremities;
        open fractures, non-unions of clavicula, tibia, humerus, rib and/or ulna fractures and
        fracture related infections.
  
        Intervention: Patients will undergo an intra-operative perfusion assessment using ICG NIR
        fluorescence imaging. For patients undergoing additional debridement procedures, perfusion
        assessment with ICG will be repeated during every procedure.
  
        Main study parameters/endpoints: The primary outcome of this study is a time-intensity curve
        with quantified perfusion parameters in traumatic soft tissue and/or skeletal injuries.
        Perfusion parameters included in the analyses are time till maximum intensity (Tmax), maximum
        intensity (Imax) the ingress rate, the normalized slope, the absolute slope and the area
        under the curve at 30, 60 and 120 seconds.
  allocation: N/A
  intervention model: Single Group Assignment
  intervention model description: The study is a prospective observational multicentre pilot study. All included patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion assessment will not affect the treatment of patients.
  primary purpose: Diagnostic
  masking: None (Open Label)
  masking description: The surgeons will be blinded as to the results of the intraoperative perfusion assessment in order to prevent bias.
  measure: Time-intensity curves
  time frame: 1 day
  description: The main endpoint of this study is an adequate time-intensity curve extracted from selected regions of interest. Adequate curves are defined as reproducible curves with accurate representation of the perfusion status. An adequate curve is characterized by a recognisable in- and outflow pattern representing the bloodflow in the tissue. Distinguishing between adequate, questionable and inadequate perfusion can only be done after comparing the measurement results.
  measure: Maximum intensity (Imax)
  time frame: 1 day
  description: As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:
  • Maximum intensity (Imax) in arbitrary units (a.u.)
  measure: Time till maximum intensity (Tmax)
  time frame: 1 day
  description: As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:
  • Time till maximum intensity (Tmax), in seconds.
  measure: The ingress rate and absolute slope
  time frame: 1 day
  description: As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:
  The ingress rate
  The absolute slope Both in arbitrary units per second (a.u./s)
  measure: The normalized slope
  time frame: 1 day
  description: As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:
  • The normalized slope in percentages per second (%/s)
  measure: The area's under the curve at 30, 60 and 120 seconds
  time frame: 1 day
  description: As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:
  • Area under the curve at 30, 60 and 120 seconds in percentages (%)
  measure: Incidence of necrotic tissue
  time frame: 90 days of necrotic
  description: Perfusion parameters will be evaluated for their correlation with the occurrence of necrotic tissue after initial debridement.
  This will be calculated as the percentage of people with inadequate perfusion parameters that develop necrotic tissue compared to people with adequate perfused tissue.
  measure: The amount of additional debridement procedures
  time frame: 90 days
  description: The number of additional debridement procedures when comparing the group with inadequate perfused tissue to the group with adequate perfused tissue.
  In numbers and percentages.
  measure: The infection incidence
  time frame: 90 days
  description: Perfusion parameters will be evaluated for their correlation with the occurrence of wound infection within 90 days after procedure. Infection defined as a red, swollen and painful area that is warm and tender to touch, possibly in combination with fever/chills, purulent effusion, positive cultures or increased infection parameters. The group with adequate perfused tissue will be compared to the group with inadequate perfusion.
  This will be in numbers and percentages.
  measure: The incidence of a fracture related infection
  time frame: 90 days
  description: Incidence of a fracture related infection will be compared between the groups with adequate and inadequate perfusion in numbers and percentages.
  measure: Lentgh of hospital stay
  time frame: 90 days
  description: The length of hospital stay will be measured in days and compared between groups with adequate and inadequate perfusion.
  measure: Amount of readmission
  time frame: 90 days
  description: The number of readmissions within 90 days associated with complications of primary problem (infection, necrosis, death) will be compared between the groups with inadequate and adequate tissue perfusion in numbers and percentages.
  arm group label: Traumatic injuries
  arm group type: Experimental
  description: Acute patients treated surgically for:
  Open deglovement (n=20)
  Crush injury (n=20)
  Open fractures (n=20)
  The setting is defined acute when there is less than 24 hours between sustaining the injury and surgery.
  Elective patients treated surgically for:
  Fracture related infection (FRI) (n=10)
  Non-union of fractures (n=50) Subdivided into 5 groups of 10.
  Elective osteosynthesis of non-union clavicula fracture N=10
  Primarily operated on N=5
  Primarily treated conservatively N=5
  Elective osteosynthesis of non-union tibia. N=10
  Elective osteosynthesis of non-union ulna. N=10
  Primarily operated on N=5
  Primarily treated conservatively N=5
  Elective osteosynthesis of non-union humerus. N=10
  Elective osteosynthesis of non-union of the rib. N=10
  intervention type: Diagnostic Test
  intervention name: Near-infrared fluorescence imaging of perfusion
  description: Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
  arm group label: Traumatic injuries
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Stefan Koning, MD
  role: Study Director
  affiliation: Leiden University Medical Center
  last name: Joost R van der Vorst, MD, PhD
  phone: +31715298528
  email: j.r.van_der_vorst@lumc.nl
  last name: Inger B Schipper, Prof. MD, Phd
  phone: +31715265025
  email: i.b.schipper@lumc.nl
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  contact: 
  country: Netherlands
  responsible party type: Principal Investigator
  investigator affiliation: Leiden University Medical Center
  investigator full name: jrvandervorst
  investigator title: Dr. Joost van der vorst, Vascular Surgeon
  mesh term: Wounds and Injuries
  sharing ipd: No